Targeted radiation therapy tested for Tough-to-Treat prostate cancer
NCT ID NCT05114746
Summary
This study is testing a new targeted radiation drug called 177Lu-PSMA-617 for men in Japan with advanced prostate cancer that has spread and is no longer responding to standard hormone therapies. The drug is designed to find and deliver radiation directly to prostate cancer cells. The main goals are to see how well the treatment shrinks tumors, how long it controls the disease, and how safe it is for patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Kashiwa, Chiba, 2778577, Japan
-
Novartis Investigative Site
Sapporo, Hokkaido, 0608648, Japan
-
Novartis Investigative Site
Kobe, Hyōgo, 6500047, Japan
-
Novartis Investigative Site
Kanazawa, Ishikawa-ken, 920 8641, Japan
-
Novartis Investigative Site
Yokohama, Kanagawa-ku, 236-0004, Japan
-
Novartis Investigative Site
Chiba, 260-8717, Japan
-
Novartis Investigative Site
Fukushima, 9601295, Japan
-
Novartis Investigative Site
Kyoto, 6068507, Japan
Conditions
Explore the condition pages connected to this study.